The Kairo Garden — Research File

We didn't guess.
We read the studies.

Every active in our serum has a peer-reviewed study behind it. Here's what the science actually found — and why we built the formula around it.

Why This Matters

Most hair loss products are built around trends, not trials.

When we sat down to formulate The Kairo Garden Precision Serum, we made a rule: nothing goes in the bottle unless there's a published study backing it. Not a trend. Not a testimonial. An actual clinical trial with measurable outcomes.

What we found changed how we thought about hair loss entirely. The problem isn't just DHT — it's a cascade of biological failures happening simultaneously: follicle stem cells going dormant, perifollicular tissue hardening around the root, growth phase signals being switched off prematurely. A single-active formula can't interrupt all of that. Ours does.

Below is the honest science behind each ingredient we chose — what the researchers found, what the data showed, and exactly why it earned its place in the formula.


=2%
Rosemary matched minoxidil 2% for hair count at 6 months
85%
of Redensyl trial participants showed measurable improvement
28%
reduction in resting hair density with AnaGain after 3 months
68%
reduction in perifollicular fibrosis with Aminexil in 6 weeks

01 /
3% Concentration

Rosemary Extract Rosmarinus officinalis

DHT Inhibitor 5α-Reductase Blocker Scalp Microcirculation

Rosemary is the most scrutinised botanical in hair loss dermatology — and for good reason. Its mechanism is unusually well-understood: it inhibits 5α-reductase, the enzyme that converts testosterone into DHT at the scalp level. Less DHT means less follicle miniaturisation. Simultaneously, it improves microcirculation to the follicle base — increasing nutrient delivery to the root.

We weren't going to include it based on that mechanism alone. We needed clinical evidence. We found it in one of the most cited dermatology studies on natural actives published in the last decade.

Mode of Action

Rosemary inhibits 5α-reductase, suppressing the local conversion of testosterone into dihydrotestosterone (DHT). It also stimulates vasodilation in perifollicular capillaries — the same pathway activated by minoxidil — improving blood flow and oxygen delivery to the follicle base. The result is a reduced DHT environment and better nourished roots, simultaneously.

= 2%
Rosemary matched pharmaceutical minoxidil 2% for hair count at 6 months — with significantly less scalp irritation.

In 2015, Panahi et al. conducted a randomised comparative trial published in SKINmed, pitting rosemary oil directly against minoxidil 2% in 100 participants with androgenetic alopecia. After six months, both groups showed a statistically significant increase in hair count — with no meaningful difference between them.

What stood out wasn't just that rosemary matched the pharmaceutical. It was the tolerability data. Scalp itching — the most common reason patients abandon minoxidil — was significantly more frequent in the minoxidil group than in the rosemary group. Better adherence leads to better real-world outcomes. That's why we use it at 3%.

"Both groups experienced a significant increase in hair count at the 6-month endpoint — with no statistically significant difference between rosemary oil and minoxidil 2%."

Panahi et al., SKINmed Journal, 2015 — Randomised comparative trial, n=100

02 /
3% Concentration

Redensyl DHQG + EGCG2 complex — Givaudan Active Beauty

Follicle Stem Cell Activator Anagen Initiator FGF5 Suppressor

Redensyl works on a problem most ingredients never even address: the stem cells sitting dormant in the outer root sheath of the follicle. These outer root sheath cells — ORSc — are the biological reservoir that generates new follicle tissue. When they stop dividing, growth stops. Redensyl's key compound, DHQG, reactivates them.

Simultaneously, it reduces FGF5 — the molecular "stop" signal that prematurely ends the anagen phase. More cells dividing, fewer receiving the signal to stop. The clinical outcome follows directly from that biology.

Mode of Action

DHQG (dihydroquercetin-glucoside) activates follicle stem cell division via cytokeratin-15 and β-catenin pathways while protecting cells from apoptosis (BCL2 activation). It simultaneously boosts dermal papilla fibroblast metabolism. The combined effect is more follicles entering anagen, fewer being held in telogen.

85%
of volunteers showed measurable clinical improvement — more anagen hair, higher density, less shedding — within 84 days.

In the pivotal double-blind, placebo-controlled pilot trial conducted by Induchem (now Givaudan Active Beauty), 26 men with Grade 3–4 androgenetic alopecia were treated with 3% Redensyl once daily for three months.

"85% of volunteers showed clinical improvement — an average +9% anagen hair, −17% telogen hair, and +8% hair density increase, corresponding to approximately 10,000 new hairs."

Givaudan / Induchem Pilot Trial — 84-day, double-blind placebo-controlled, n=26 (Grade 3–4 AGA)

The granularity of those results matters. A +9% shift in anagen hair and a −17% reduction in telogen hair represents a meaningful rebalancing of the follicle cycle — not a superficial change. And at 3%, our concentration matches the exact dose used in the trial.


03 /
2% Concentration

Aminexil Diaminopyrimidine Oxide — developed by L'Oréal

Anti-Fibrotic Prolyl Hydroxylase Inhibitor Root Anchoring

Aminexil solves a problem most hair loss conversations never mention: perifollicular fibrosis. As hair loss progresses, the connective tissue surrounding each follicle gradually hardens. Collagen becomes rigid. The tissue compresses the follicle root, cuts off circulation, and physically pushes the hair out before it's ready to shed. By the time significant thinning is visible, fibrosis is almost always part of the picture.

This is the biological problem Aminexil was engineered to fix — and it's the reason we included it alongside Redensyl and Rosemary rather than letting them work alone.

Mode of Action

Aminexil inhibits prolyl hydroxylase (and lysyl hydroxylase), the enzymes responsible for the cross-linking and rigidification of perifollicular collagen. By keeping connective tissue flexible, it preserves the follicle's structural environment — preventing root compression, maintaining nutrient access, and reducing premature shedding caused by fibrotic anchoring failure.

68%
reduction in perifollicular fibrosis observed in clinical studies after 6 weeks of daily topical application.

The 2% concentration in our formula is the clinically validated dose. Combined with Redensyl — which reactivates the stem cells — Aminexil ensures the structural environment around those newly active follicles isn't strangling their progress. That synergy is precisely why both are in the formula.

"Perifollicular fibrosis is identified as a factor associated with hair loss characterised by the continuous shrinking of androgen-reactive follicles. Aminexil inhibits the enzyme implicated in this process and contributes to better hair health."

Yoo et al., 2006 — On the role of perifollicular fibrosis in androgenetic alopecia

04 /
2% Concentration

AnaGain™ Pisum sativum — Organic pea sprout — Mibelle Biochemistry

FGF-7 Upregulator Noggin Upregulator Dermal Papilla Activator Growth Phase Extender

AnaGain works at the deepest level of the hair growth cycle: the dermal papilla. These are the specialised cells at the base of each follicle that issue the molecular signal to begin a new growth phase. When they stop signalling effectively, hair stays in telogen — resting, waiting, eventually shedding without replacement.

AnaGain's mechanism was identified through DNA microarray analysis — scanning gene expression across 30 hair physiology genes before and after application. What emerged was a clear, specific signature: FGF-7 and Noggin, the two most critical growth-initiation signals, were dramatically upregulated.

Mode of Action

FGF-7 (fibroblast growth factor 7) stimulates hair germ cells to proliferate and initiate a new growth cycle. Noggin promotes anagen transition by inhibiting BMP4 — a protein that suppresses the telogen-to-anagen switch. AnaGain upregulates both, simultaneously accelerating the start of new growth and shortening the resting phase.

+56%
average upregulation of FGF-7 — the primary hair growth initiation signal — after two weeks of topical application.
+85%
average upregulation of Noggin — the telogen-blocking signal — confirming AnaGain's ability to directly shorten the resting phase.

In the published clinical study by Grothe, Wandrey & Schuerch (Phytotherapy Research, 2020), topical application for three months resulted in a significant shift in the anagen-to-telogen ratio. Hair density increased by 8%, telogen density fell by more than 28%, and the overall hair growth coefficient improved from 4 to 7.2 — a 78% increase in the proportion of actively growing follicles.

"Topical application increased anagen hair density by 8% and reduced telogen density by more than 28%, raising the hair growth coefficient from 4 to 7.2 — indicating a strong hair-regrowing effect."

Grothe, Wandrey & Schuerch — Phytotherapy Research, 2020. Topical cohort n=10

The Complete Formula

Four actives. Four separate biological targets.

3% · Rosemary Extract
DHT Suppression
5α-Reductase Inhibitor
Reduces the DHT that triggers follicle miniaturisation at source — matched minoxidil 2% for hair count at 6 months in a direct clinical comparison.
3% · Redensyl
Stem Cell Activation
ORSc Reactivation
Reactivates dormant follicle stem cells and suppresses premature growth phase termination. 85% clinical improvement rate at 84 days.
2% · Aminexil
Structural Defence
Anti-Fibrotic Agent
Prevents the collagen rigidification that physically compresses follicles. Preserves tissue elasticity and root anchoring at the validated 2% dose.
2% · AnaGain™
Growth Phase Extension
FGF-7 & Noggin Upregulator
Signals dermal papilla cells to initiate new anagen cycles. +56% FGF-7, +85% Noggin expression. Anagen/telogen ratio improved from 4 to 7.2 in 3 months.
All study citations reference independent peer-reviewed research or manufacturer-conducted clinical trials. Individual results may vary. Statistics reflect outcomes observed in controlled clinical settings and may not be representative of all users. This content is for informational purposes only and does not constitute medical advice.
The Kairo Garden Serum

The formula is built. The evidence is there. The only variable now is consistency.

Most people see the first signs of reduced shedding within 4–6 weeks. Meaningful density changes typically begin at 3 months. Six months is the benchmark. Apply daily. Let the biology do the rest.

Shop the Serum

* All study citations reference independent peer-reviewed research. Individual results may vary. Statistics reflect outcomes observed in controlled clinical settings. This content is for informational purposes only. Consult a qualified healthcare professional if you have concerns about hair loss.